1st International Conference, Freiburg, June 11-12, 1999: Erythropoietin in radiation oncology - A review

Oncology

Volumn 58, Issue 2, 2000, Pages 175-182

  Henke, Michael ^a   Guttenberger, Roland ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Anemia; Erythropoietin; Hemoglobin; Hypoxia; Oxygenation; Radiotherapy; Tumor

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD TRANSFUSION; CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; HUMAN; HYPOXIA; MAJOR CLINICAL STUDY; NONHUMAN; OXYGENATION; PRIORITY JOURNAL; RAT; SIDE EFFECT; ANIMAL; BLOOD; CELL HYPOXIA; EXPERIMENTAL NEOPLASM; METABOLISM; NEOPLASM; QUALITY OF LIFE; RADIATION EXPOSURE; TIME; TREATMENT OUTCOME;

ANEMIA; ANIMALS; CELL HYPOXIA; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034132195     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012096     Document Type: Conference Paper

References (39)

1. Bush RS: The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys 1986;12:2047-2050.
2. Manegold C: The causes and prognostic significance of low hemoglobin levels in tumor patients. Strahlenther Onkol 1998;174(suppl 4): 17-19.
3. Vaupel P, Kelleher DK (eds): Tumor Hypoxia. Pathophysiology, Clinical Significance and Therapeutic Perspectives. Stuttgart, Wissenschaftliche Verlagsgesellschaft, 1999.
4. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45-50.
5. Hoeckel M, Schlenger K, Aral B, Mitze M, Schäffer U, Vaupel P: Association between tumor hypotia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-4515.
6. Nordsmark M, Overgaard M, Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41:31-39.
7. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW: Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-943.
8. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38:285-289.
9. Höckel M, Schlenger K, Höckel S, Vaupel P: Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999; 59:4525-4528.
10. Stadler P, Becker A, Feldmann HJ, Hansgen G, Dunst J, Wurschmidt F, Molls M: Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999;44:749-754.
11. Giaccia AJ, Koumenis C, Denko N: The influence of tumor hypoxia on malignant progression; in Vaupel P, Kelleher DK (eds): Tumor Hypoxia. Pathophysiology, Clinical Significance and Therapeutic Perspectives. Stuttgart, Wissenschaftliche Verlagsgesellschaft, 1999, pp 115-124.
12. Frommhold H, Guttenberger R, Henke M: The impact of blood hemoglobin content on the outcome of radiotherapy. Strahlenther Onkol 1998;174 (suppl 4):31-34.
13. Hirst DG: Anemia: A problem or an opportunity in radiotherapy? Int J Radiat Oncol Biol Phys 1986;12:2009-2017.
14. Hirst DG, Wood PJ: The adaptive response of mouse tumours to anaemia and retransfusion. Int J Radiat Biol Relat Stud Phys Chem Med 1987;51:597-609.
15. Durand RE, Sham E: The lifetime of hypoxic human tumor cells. Int J Radiat Oncol Biol Phys 1998;42:711-715.
16. Kelleher DK, Matthiensen U, Thews O, Vaupel P: Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 1996;56:4728-4734.
17. Kelleher DK, Matthiensen U, Thews O, Vaupel P: Tumor oxygenation in anemic rats: Effects of erythropoietin treatment versus red blood cell transfusion. Acta Oncol 1995;34: 379-384.
18. Thews O, Koenig R, Kelleher DK, Kutzner J, Vaupel P: Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 1998;78:752-756.
19. Henke M, Momm F, Guttenberger R: Erythropoietin for patients undergoing radiotherapy. The Freiburg experience: in Vaupel P, Kelleher DK (eds): Tumor Hypoxia. Pathophysiology, Clinical Significance and Therapeutic Perspectives. Stuttgart, Wissenschaftliche Verlagsgesellschaft, 1999, pp 91-97.
20. Macdougall IC, Cavill I, Hulme B, Bain B, McGregor E, McKay P, Sanders E, Coles GA, Williams JD: Detection of functional iron deficiency during erythropoietin treatment: A new approach. Br Med J 1992;304:225-226.
21. Braun J, Lindner K, Schreiber M, Heidler RA, Horl WH: Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant 1997;12:1173-1181.
22. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP: Transfusion medicine. First of two parts - blood transfusion. N Engl J Med 1999; 340:438-447.
23. Shirwadkar S, Blajchman MA, Frame B, Singal DP: Effect of allogeneic blood transfusion on solid tumor growth and pulmonary metastases in mice. J Cancer Res Clin Oncol 1992;118: 176-180.
24. Blajchman MA, Bardossy L, Carmen R, Sastry A, Singal DP: Allogeneic blood transfusion-induced enhancement of tumor growth: Two animal models showing amelioration by leukodepletion and passive transfer using spleen cells. Blood 1993;81:1880-1882.
25. Busch OR, Hop WC, Hoynck van Papendrecht MA, Marquet RL, Jeekel J: Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993;328:1372-1376.
26. Grau C, Horsman MR, Overgaard J: Influence of carboxyhemoglobin level on tumor growth, blood flow, and radiation response in an experimental model. Int J Radiat Oncol Biol Phys 1992;22:421-424.
27. Overgaard J, Nielsen JF, Grau C: Effect of carboxyhemoglobin on tumor oxygen unloading capacity in patients with squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1992;22:407-410.
28. Lavey RS, Dempsey WH: Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 1993;27:1147-1152.
29. Vijayakumar S, Roach M, Wara W, Chan SK, Ewing C, Rubin S, Sutton H, Halpern H, Awan A, Houghton A, Quiet C, Weichselbaum R: Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: Preliminary results of a randomized, open-labeled, phase II trial. Im J Radiat Oncol Biol Phys 1993;26:721-729.
30. Dusenbery KE, McGuire WA, Holt PJ, Carson LF, Fowler JM, Twiggs LB, Potish RA: Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 1994;29:1079-1084.
31. Case DC, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones SE, Keller AM, Kugler JW, Michels CR, Salmon SE, Silver RT, Storniolo AM, Wampler GL, Dooley CM, Larholt KM, Nelson RA, Abels RI: Recombinant human erythropoietin therapy for anemic cancer patients on combinat ion chemotherapy. J Natl Cancer Inst 1993;85:801-806.
32. Henry DH, Abels RI: Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies. Semin Oncol 1994;21(suppl 3):21-28.
33. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H: Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994;73:2535-2542.
34. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
35. Demetri GD, Kris M, Wade J, Degos L, Cella D: Quality-of-life benefit in chemotherapy patients treated with epoetin alpha is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16: 3412-3425.
36. Antonadou D, Cardamakis E, Sarris G, Tzigounis V, Throuvalas V: Effect of the administration of recombinant human crythropoietin in patients with pelvic malignancies during radiotherapy. Radiother Oncol 1998;S48:483.
37. Glaser G, Millesi W, Wanschitz F, Schüll B, Lang S, Leitha T, Kornek GV: R-HuErythropoietin treatment increases efficacy of neoadjuvant radiochemotherapy and improves cancer free survival of patients with oral squamous cell carcinoma: A 17 month follow-up. Proc Am Soc Clin Oncol 1999;18:399a.
38. Henke M, Guttenberger R, Barke A, Pajonk F, Pötter R, Frommhold H: Erythropoietin for patients undergoing radiotherapy: A pilot study. Radiother Oncol 1999;50:185-190.
39. Guttenberger R, Lutterbach J, Roth A, Röser S, Schindler R, Henke M, Frommhold H: Hemoglobin levels predict local regional control after postoperative radiotherapy for advanced head and neck cancer. Eur J Cancer 1997;33(suppl): 102-103.